Markus Joerger, Sjaak A. Burgers, Paul Baas, Egbert F. Smit, Tjeerd J. Haitjema, Martin P. L. Bard, Valerie D. Doodeman, Paul H. M. Smits, Andrew Vincent, Alwin D. R. Huitema, Jos H. Beijnen and Jan H. M. Schellens Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy Cancer 118
Article first published online: 28 SEP 2011 | DOI: 10.1002/cncr.26562
To the authors' knowledge, this is the first prospective study in patients with advanced nonsmall cell lung cancer (NSCLC) to describe predictive germline polymorphisms not only for platinum-gemcitabine clinical activity (excision repair cross-complementation group 1 [ERCC1] and xeroderma pigmentosum group A member 10 [XPD10]), but also for toxicity (glutathione S-transferase π 1 [GSTP1], adenosine triphosphate-dependent DNA helicase Q1 [RECQ1], and cytidine deaminase [CDA]). The results indicate that nonplatinum-containing chemotherapy for carriers of the ERCC1 T allele or the XPD10 G allele should be studied prospectively.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field